Clinical Trials Logo

Follicular Lymphoma, Grade 1 clinical trials

View clinical trials related to Follicular Lymphoma, Grade 1.

Filter by:
  • None
  • Page 1

NCT ID: NCT03919175 Terminated - Lymphoma Clinical Trials

Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

This research is being done to assess Umbralisib and Rituximab as a first line therapy for Follicular Lymphoma or Marginal Zone Lymphoma.

NCT ID: NCT02966730 Terminated - Follicular Lymphoma Clinical Trials

Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy

Start date: November 2016
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to find out how successful ibrutinib is at putting follicular lymphoma into full remission. In this study, remission will be determined by achieving a normal PET scan after treatment. A PET scan is an imaging test that looks for active lymphoma. People who don't have a complete remission on PET after their first treatment are at high risk for having their lymphoma return. This study will investigate if ibrutinib will help participants achieve a complete remission without giving additional chemotherapy. The study will also investigate any possible side effects of the study drug ibrutinib.

NCT ID: NCT02710643 Completed - Clinical trials for Follicular Lymphoma, Grade 1

"MIRO" Molecularly Oriented Immuno-radio-therapy

FIL_MIRO
Start date: October 2014
Phase: Phase 2
Study type: Interventional

Phase II prospective multicenter study for stage I/II Follicular Lymphoma treated with involved-field radiotherapy (IFRT) at doses of 24 Gy) with or without Ofatumumab for 8 weekly doses on molecular basis. Patients with positive basal Bcl-2 will be followed every 3 months and with Bcl-2 detection every 6 months for 3 years. Patient with negative basal Bcl-2 will be followed every 3 months without further Bcl-2 detection. Ofatumumab treatment will be administered to: 1. Patients with positive basal PCR for Bcl-2-IgH rearrangement in BM and/or PB, resulting still positive after IFRT; 2. Patients with positive basal PCR for Bcl-2-IgH in